Emmanuel Macron’s trip this Thursday, November 23 to Chartres to unveil a new industrial relocation project in the health sector. An investment of more than two billion euros from the Danish laboratory Novo Nordisk in the production of drugs for diabetes and obesity, which could put an end to the drug shortages that France has regularly experienced for three years. Explanations from economist Frédéric Bizard, founding president of the Institute of Health.
rf-3-france
Shortage of medicines: “Structural reforms must be made”
